Advertisement

Topics

FDA grants priority review to Merck’s Keytruda for cervical cancer

01:56 EDT 14 Mar 2018 | Pharmaceutical Business Review

Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) has been granted priority review designation by the US Food and Drug Administration (FDA) for the treatment of advanced cervical cancer.

Original Article: FDA grants priority review to Merck’s Keytruda for cervical cancer

NEXT ARTICLE

More From BioPortfolio on "FDA grants priority review to Merck’s Keytruda for cervical cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...